Literature DB >> 23665646

Contamination risk of 100% autologous serum eye drops in management of ocular surface diseases.

Onsiri Thanathanee1, Warachaya Phanphruk, Orapin Anutarapongpan, Amornrat Romphruk, Olan Suwan-Apichon.   

Abstract

PURPOSE: To evaluate the sterility and safety of 100% nonpreserved, autologous, serum eye drop treatment in patients with ocular surface diseases.
METHODS: A total of 147 autologous serum bottles (294 samples) from 21 patients with ocular surface diseases were included. Seven bottles with autologous serum were prepared for each patient, and each bottle was used for only 1 day, then discarded. Two samples from each bottle were taken (before use and after 24 hours of use) and then cultured in standard media. The culture plates were held for at least 6 weeks or until no growth could be confirmed. To monitor safety, all patients were admitted and evaluated for the occurrence of infection.
RESULTS: In the pretreatment group, 4 samples from 4 patients (1.36%) were positive for bacteria and 7 samples from 7 patients (2.38%) were positive for fungi. In the 24-hour-after-treatment group, 1 culture (0.34%) was positive for bacteria, and 6 samples (2.04%) from 6 patients were positive for fungi. Aspergillus spp and Fonsecaea spp were the most common organisms identified in any of the cultures. Neither clinical nor microbiological evidence of infection was demonstrated in any patient during the treatment or follow-up periods.
CONCLUSIONS: Although no ocular surface infection was observed, the patients under 100% autologous serum eye drops therapy should be closely monitored for clinical evidence of fungal and bacterial infections.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23665646     DOI: 10.1097/ICO.0b013e3182910036

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  4 in total

Review 1.  Platelet gel: a new therapeutic tool with great potential.

Authors:  Andrea Piccin; Angela M Di Pierro; Lucia Canzian; Marco Primerano; Daisy Corvetta; Giovanni Negri; Guido Mazzoleni; Günther Gastl; Michael Steurer; Ivo Gentilini; Klaus Eisendle; Fabrizio Fontanella
Journal:  Blood Transfus       Date:  2016-07-25       Impact factor: 3.443

2.  Stability of epidermal growth factor, fibronectin, and alpha-2-macroglobulin in canine serum under different storage conditions.

Authors:  Cecile Briffod; Christian Bédard; Maria Vanore
Journal:  Can J Vet Res       Date:  2019-10       Impact factor: 1.310

3.  Amniotic membrane extract eye drops for ocular surface diseases: use and clinical outcome in real-world practice.

Authors:  Noelia Sabater-Cruz; Marc Figueras-Roca; Miriam Ferrán-Fuertes; Elba Agustí; Eva M Martínez-Conesa; María Luisa Pérez-Rodríguez; Anna Vilarrodona; Ricardo P Casaroli-Marano
Journal:  Int Ophthalmol       Date:  2021-04-17       Impact factor: 2.031

4.  Outcomes of phacoemulsification in patients with chronic ocular graft-versus-host disease.

Authors:  Ujwala S Saboo; Francisco Amparo; Hasanain Shikari; Ula V Jurkunas; Reza Dana
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-01-27       Impact factor: 3.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.